Defining medication adherence in individual patients

被引:36
作者
Morrison, Alan [1 ]
Stauffer, Melissa E. [1 ]
Kaufman, Anna S. [1 ]
机构
[1] ScribCo, Effort, PA 18330 USA
关键词
pharmacokinetic adherence; drug therapy/utilization; drug administration schedule; patient compliance; adalimumab; pharmacokinetics; RHEUMATOID-ARTHRITIS; CLINICAL-RESPONSE; CROHNS-DISEASE; ADALIMUMAB; ASSOCIATION; PHARMACOKINETICS; ANTIBODIES; REMISSION;
D O I
10.2147/PPA.S86249
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The classification of patients as adherent or non-adherent to medications is typically based on an arbitrary threshold for the proportion of prescribed doses taken. Here, we define a patient as pharmacokinetically adherent if the serum drug levels resulting from his/her pattern of medication-taking behavior remained within the therapeutic range. Methods: We used pharmacokinetic modeling to calculate serum drug levels in patients whose patterns of dosing were recorded by a medication event monitoring system. Medication event monitoring system data were from a previously published study of seven psoriasis patients prescribed 40 mg subcutaneous adalimumab at 14-day intervals for 1 year. Daily serum concentrations of adalimumab were calculated and compared with a known therapeutic threshold. Results: None of the seven patients took adalimumab precisely every 14 days. Three patients who took adalimumab at intervals of 6-26 days could be classified as pharmacokinetically adherent, because their daily adalimumab serum concentration never fell below the therapeutic threshold. The four other patients, who took adalimumab at intervals of 7-93 days, could be classified as pharmacokinetically non-adherent, because their adalimumab serum concentration fell below the therapeutic threshold on 3.5%-71.3% of days. Conclusion: Patients with varying patterns of adalimumab dosing could be classified as pharmacokinetically adherent or non-adherent according to whether or not their serum drug concentrations remained within the therapeutic range.
引用
收藏
页码:893 / 897
页数:5
相关论文
共 17 条
[1]   Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis [J].
Bartelds, Geertje M. ;
Wijbrandts, Carla A. ;
Nurmohamed, Michael T. ;
Stapel, Steven ;
Lems, Willem F. ;
Aarden, Lucien ;
Dijkmans, Ben A. C. ;
Tak, Paul Peter ;
Wolbink, Gerrit Jan .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (07) :921-926
[2]   Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up [J].
Bartelds, Geertje M. ;
Krieckaert, Charlotte L. M. ;
Nurmohamed, Michael T. ;
van Schouwenburg, Pauline A. ;
Lems, Willem F. ;
Twisk, Jos W. R. ;
Dijkmans, A. C. ;
Aarden, Lucien ;
Wolbink, Gerrit Jan .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (14) :1460-1468
[3]   Serum Adalimumab Concentration and Clinical Remission in Patients with Crohn's Disease [J].
Chiu, Yi-Lin ;
Rubin, David T. ;
Vermeire, Severine ;
Louis, Edouard ;
Robinson, Anne M. ;
Lomax, Kathleen G. ;
Pollack, Paul F. ;
Paulson, Susan K. .
INFLAMMATORY BOWEL DISEASES, 2013, 19 (06) :1112-1122
[4]   American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006 [J].
Clark, M. ;
Colombel, J.-F. ;
Feagan, B. C. ;
Fedorak, K. N. ;
Hanauer, S. B. ;
Kamm, M. A. ;
Mayer, L. ;
Regueiro, C. ;
Rutgeerts, P. ;
Sandborn, W. J. ;
Sands, B. E. ;
Schreiber, S. ;
Targan, S. ;
Travis, S. ;
Vermeire, S. .
GASTROENTEROLOGY, 2007, 133 (01) :312-339
[5]   A systematic review of the associations between dose regimens and medication compliance [J].
Claxton, AJ ;
Cramer, J ;
Pierce, C .
CLINICAL THERAPEUTICS, 2001, 23 (08) :1296-1310
[6]   Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial [J].
Colombel, Jean-Frederic ;
Sandborn, William J. ;
Rutgeerts, Paul ;
Enns, Robert ;
Hanauer, Stephen B. ;
Panaccione, Remo ;
Schreiber, Stefan ;
Byczkowski, Dan ;
Li, Ju ;
Kent, Jeffrey D. ;
Pollack, Paul F. .
GASTROENTEROLOGY, 2007, 132 (01) :52-65
[7]   Medication compliance and persistence: Terminology and definitions [J].
Cramer, Joyce A. ;
Roy, Anuja ;
Burrell, Anita ;
Fairchild, Carol J. ;
Fuldeore, Mahesh J. ;
Ollendorf, Daniel A. ;
Wong, Peter K. .
VALUE IN HEALTH, 2008, 11 (01) :44-47
[8]  
den Broeder A, 2002, J RHEUMATOL, V29, P2288
[9]  
Haynes RB, 1976, COMPLIANCE THERAPEUT, P26
[10]   Modeling and simulation of adherence:: Approaches and applications in therapeutics [J].
Kenna, LA ;
Labbé, L ;
Barrett, JS ;
Pfister, M .
AAPS JOURNAL, 2005, 7 (02) :E390-E407